Results 201 to 210 of about 177,994 (348)

Snapshots of Motion: A Novel Structural Intermediate Reveals Conserved Dynamics in Archaeal DNA Ligases

Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 6, Page 1245-1258, June 2026.
ABSTRACT We present the first x‐ray crystallographic structural evidence of an archaeal DNA ligase showing the AMP covalent adduct together with further cofactor hydrolysis, capturing a transient intermediary in the first step of the ligation reaction, triggered by the pyrophosphate hydrolysis.
A. X. Quintana‐Armas, E. Flores‐Hernández, C. Cardona‐Félix, E. Rudiño‐Piñera   +3 more
wiley   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

Benzo[a]pyrene downregulation of BRCA1 [PDF]

, 1999
Chris Jones
openalex   +1 more source

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, Volume 88, Issue 7, Page 1373-1384, June 2026.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source

Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification. [PDF]

EBioMedicine
Fortuno C, Zhang J, Koufariotis LT, Hollway G, Wood S, Pearson JV, Simpson PT, Lakhani SR, McCart Reed AE, Thorne H, Mann GB, Skandarajah AR, Devereux L, Zhao Q, De Silva DL, Lindeman GJ, Waring P, James PA, Campbell I, Spurdle AB, Waddell N.   +20 more
europepmc   +1 more source

Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.

, 2016
Da Li, Qi‐Jun Wu, Fangfang Bi, Si-Lei Chen, Yiming Zhou, Yue Zhao, Qing Yang   +6 more
openalex  

Experts weigh in on BRCA1/2 mutations and prophylactic surgeries [PDF]

, 2011
Carrie Printz
openalex   +1 more source

Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis

Immunology, Volume 178, Issue 2, Page 209-217, June 2026.
Microbial imbalance, dysbiosis, plays a role in ovarian carcinogenesis by interacting with the immune system and altering inflammatory pathways, notably Th17 pathways. In contrast, eubiosis, characterised by Lactobacillus dominance, protects against infections and maintains hormone metabolism.
Wafa Babay, Mariem Garci, Ahmed Baligh Laaribi, Nabil Mathlouthi, Imene Ouzari   +4 more
wiley   +1 more source

Rapid and sensitive detection of BRCA1/2 mutations in a diagnostic setting: Comparison of two high-resolution melting platforms [PDF]

, 2008
Claes, Kathleen, Coene, Ilse, De Leeneer, Kim, De Paepe, Anne, Poppe, Bruce   +4 more
core   +1 more source

Pancancer Fine‐Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma

Advanced Science, Volume 13, Issue 25, 4 May 2026.
This study identifies mutation‐intolerant genes (MIGs), which are mutationally constrained in tumors despite normal‐tissue variability. Using miDriver, the authors pinpoint MIGs essential for tumor‐intrinsic fitness and immune evasion. Focusing on CHEK1, they show it drives tumor fitness and sculpts an immunosuppressive niche via the MIF–CD74 axis ...
Tao Wang, Hongyu Zhao, Xiaojie Sun, Yuqi Ding, Zhipeng Zhu, Xiaotong Yu, Rongyi Zhu, Dan Wang, Kailong Li, Yang Liu, Li‐Bin Wang, Xiaolu Zhao, Baojun Suo, Hongsen Bi, Peipei Zhang, Tong Liu, Fengbiao Mao   +16 more
wiley   +1 more source